EP Patent

EP2305667A3 — Nilotinib intermediates and preparation thereof

Assigned to Teva Pharmaceutical Industries Ltd · Expires 2011-05-11 · 15y expired

What this patent protects

Nilotinib•3HCl and its crystalline forms are described, and processes for the preparation of the same.

USPTO Abstract

Nilotinib•3HCl and its crystalline forms are described, and processes for the preparation of the same.

Drugs covered by this patent

Patent Metadata

Patent number
EP2305667A3
Jurisdiction
EP
Classification
—
Expires
2011-05-11
Drug substance claim
No
Drug product claim
No
Assignee
Teva Pharmaceutical Industries Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.